Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy
The pharmaceutical company Lexeo Therapeutics has announced positive updates from their phase I/II trial of the gene therapy LX2006 to treat cardiomyopathy in Friedreich’s ataxia (FA).  Interim data has shown […]
Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy Read More »